Navigation Links
Arthritis Foundation and Takeda Launch First-Ever National Gout Public Service Announcement (PSA) Campaign, Urging People Living With Gout to 'Keep Enjoying Life's Simple Pleasures'
Date:9/13/2010

ATLANTA and DEERFIELD, Ill., Sept. 13 /PRNewswire/ -- The Arthritis Foundation and Takeda Pharmaceuticals North America, Inc., today announced the launch of a new educational campaign, Gout Living, to help increase understanding and encourage better management of gout. The campaign, which includes the first-ever gout public service announcements (PSAs), aims to encourage those living with the disease to be proactive about their health. The PSAs, which will be available via television, radio and print outlets, emphasize that living with gout doesn't have to mean missing out on life's special moments.

As part of the initiative, educational information and valuable resources are available on the Gout Living website, www.goutliving.org. The website features tools like a gout attack tracker, tips to start a conversation about gout with a doctor, and information for family, friends and caregivers of people with gout, as well as how to locate a local Arthritis Foundation office.  

For more information and to view the full multimedia news release, please visit www.goutlivingPSA.com.

"Gout is a common yet often overlooked arthritic disease, and the Arthritis Foundation is dedicated to improving the lives of those with arthritis and related diseases, including gout," says John Hardin, M.D., vice president of research of the Arthritis Foundation. "GoutLiving.org provides people with gout and their loved ones with information about ways to manage gout and keep it under control. Learning about this chronic illness is an important first step, and we are excited to be able to offer new and valuable resources to the gout community."

There are more than 100 types of arthritis, and gout, a painful and chronic disease, is one of them. It is actually the most common form of inflammatory arthritis in men and affects an estimated 6 million people in the United States.  

"Takeda is committed to increasing understanding of gout and fostering meaningful dialogue about the disease," says Robert Spanheimer, M.D., vice president of medical and scientific affairs at Takeda. "We are pleased to partner with the Arthritis Foundation to provide tools and resources needed to increase gout education and enhance communication around gout management."

About Gout

Gout is a chronic, metabolic disease affecting approximately 6 million Americans and is the most common form of inflammatory arthritis in men. The underlying cause of gout is hyperuricemia, a condition characterized by elevated levels of uric acid in the blood.  

A gout attack, or "flare," occurs when excess uric acid in the body begins to form crystals, triggering an inflammatory response in the joints or soft tissue causing extreme discomfort. While gout can affect several different joints, including elbows, knees and wrists, patients most commonly experience attacks in the big toe. The pain of a gout attack may interfere with everyday activities, including work and family events.

In addition to recommended diet and lifestyle changes, experts recognize that achieving and maintaining a healthy uric acid level in the body of less than 6.0 mg/dL can help reduce the risk of future attacks.

About the Arthritis Foundation

The mission of the Arthritis Foundation is to improve lives through leadership in the prevention, control and cure of arthritis and related diseases.  

The Arthritis Foundation is the leading health organization addressing the needs of some 46 million Americans living with doctor-diagnosed arthritis, the nation's most common cause of disability.

The Arthritis Foundation pursues its mission through a focus on:

  • Research: The Arthritis Foundation is the largest nonprofit contributor to arthritis research in the world, advancing cutting-edge research in search of a cure for arthritis.
  • Public Health: The Arthritis Foundation aims to increase public awareness of arthritis as the most common cause of disability, to prevent arthritis whenever possible, and to promote early diagnosis and access to the resources people with arthritis need to cope with their disease.
  • Public Policy: The Arthritis Foundation works at both the national and local levels to advance legislative policy issues on behalf of the 46 million adults and approximately 300,000 children in America with doctor-diagnosed arthritis.

The Arthritis Foundation offers resources to people who live with gout and other forms of arthritis through many communications vehicles, such as the magazine Arthritis Today; through local offices across the country that offer resources and programs for people with arthritis; and through its website, www.arthritis.org.

About Takeda Pharmaceuticals North America, Inc. and Takeda Global Research & Development Center, Inc.

Based in Deerfield, Ill., Takeda Pharmaceuticals North America, Inc. and Takeda Global Research & Development Center, Inc. are subsidiaries of Takeda Pharmaceutical Company Limited, the largest pharmaceutical company in Japan. The respective companies currently market oral diabetes, insomnia, rheumatology and gastroenterology treatments, and seek to bring innovative products to patients through a pipeline that includes compounds in development for diabetes, cardiovascular disease, gastroenterology, neurology and other conditions. To learn more about these Takeda companies, visit www.tpna.com.


'/>"/>
SOURCE The Arthritis Foundation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. ORENCIA(R) (abatacept) Supplemental Biologics License Application for Juvenile Idiopathic Arthritis Accepted by FDA for Filing and Review
2. New Risk Gene for Rheumatoid Arthritis and Lupus Opens Door to More Effective Treatments
3. Trubion Announces Preliminary Analysis of Phase IIb Results With TRU-015 in Rheumatoid Arthritis
4. Targeted Genetics Reports on Recombinant DNA Advisory Committee (RAC) Review of its Phase 1/2 Trial of tgAAC94 for Rheumatoid Arthritis
5. Evidence of Benefit Lacking for Many Common Ways of Treating Osteoarthritis of the Knee
6. Cost-Effectiveness Study Supports Use of EUFLEXXA(TM) by Rheumatologists for Pain Relief in Patients with Knee Osteoarthritis
7. CIMZIA(R) (certolizumab pegol), Significantly Reduces Structural Damage and Rheumatoid Arthritis Signs & Symptoms for Up to One Year
8. Phase 3 Data Show New Anti-TNF, Golimumab, Significantly Improved Arthritis, Skin and Nail Manifestations in Patients with Psoriatic Arthritis
9. Two Pivotal Phase III Studies for Roches ACTEMRA(TM) (tocilizumab) Demonstrate Significant Improvement in Rheumatoid Arthritis Symptoms
10. Trubion Pharmaceuticals Announces Presentation of Positive Data From Phase IIb and Re-treatment Studies With TRU-015 in Patients With Rheumatoid Arthritis
11. Five-Year Data Demonstrate Long-Term Efficacy and Safety with ORENCIA(R) (abatacept) in Adults with Rheumatoid Arthritis Who had an Inadequate Response to Methotrexate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... -- LexisNexis® Risk Solutions, a leading provider of data, ... LexisNexis Provider Performance Monitor , a clinical ... the quality and efficiency of provider networks through ... measuring provider performance through Provider Performance Monitor, payers ... improve the patient experience and reduce costs, as ...
(Date:2/10/2016)... 2016 Mast Therapeutics, Inc. (NYSE ... for sickle cell disease and heart failure, today announced ... units at a price to the public of $0.275 ... the Company,s common stock and one warrant to purchase ... exercise price of $0.42 per share. The warrants are ...
(Date:2/10/2016)... 10, 2016 ALSP, Inc. announced that it has ... for Medical Affairs in preparation for its move into clinical ... PhD, CEO, stated, "We are pleased to welcome Dallas ... working with an individual of such practical knowledge and far-reaching ... drawing deeply on his broad experience and success as a ...
Breaking Medicine Technology:
(Date:2/10/2016)... ... 10, 2016 , ... Gout is like no other joint pain. It strikes ... with intense swelling and redness. It is triggered by the crystallization of uric acid ... the most susceptible, according to the February 2016 issue of Harvard Men's Health Watch. ...
(Date:2/10/2016)... ... 10, 2016 , ... AHRA: The Association for Medical Imaging ... Fox will serve as keynote speaker at the organization’s 2016 Spring Conference. Fox’s ... more effectively communicate with their own organizational staff and leadership. , “I ...
(Date:2/10/2016)... MN (PRWEB) , ... February 10, 2016 , ... ... that it will attend the Ohio Safety Congress and Expo event March 9-11, ... at the Greater Columbus Convention Center. , As the longest running and ...
(Date:2/10/2016)... (PRWEB) , ... February 10, 2016 , ... ... revolutionary, biocompatible columns and accessories. These PEEK-lined stainless steel (PLS) columns combine the ... a solution that ensures the integrity of biological samples while operating at ultra-high ...
(Date:2/10/2016)... , ... February 10, 2016 , ... Workrite Ergonomics, who ... that has evolved from humble beginnings to being an internationally recognized leader in their ... we are today”, said Charlie Lawrence, President of Workrite. “Workrite recognized the importance ...
Breaking Medicine News(10 mins):